VolitionRX’s (VNRX) Buy Rating Reiterated at Maxim Group

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating restated by stock analysts at Maxim Group in a report issued on Thursday,Benzinga reports. They currently have a $4.00 price target on the medical research company’s stock. Maxim Group’s target price indicates a potential upside of 179.13% from the stock’s current price.

A number of other equities analysts have also weighed in on the stock. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. HC Wainwright dropped their target price on VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Finally, Citigroup cut VolitionRX to a “hold” rating in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, VolitionRX currently has an average rating of “Hold” and a consensus price target of $28.00.

VolitionRX Stock Up 4.6%

Shares of VNRX traded up $0.06 during trading hours on Thursday, reaching $1.43. The stock had a trading volume of 222,566 shares, compared to its average volume of 429,085. The company has a market cap of $12.37 million, a P/E ratio of -0.34 and a beta of 1.04. VolitionRX has a 52 week low of $1.30 and a 52 week high of $18.80. The firm has a 50-day moving average of $2.53 and a 200 day moving average of $4.07.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The business had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.52 million. As a group, equities analysts expect that VolitionRX will post -2.4 earnings per share for the current year.

Hedge Funds Weigh In On VolitionRX

Institutional investors and hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. bought a new position in shares of VolitionRX during the second quarter worth approximately $52,000. Virtu Financial LLC bought a new position in shares of VolitionRX in the third quarter worth $28,000. Citadel Advisors LLC raised its position in shares of VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after buying an additional 135,775 shares in the last quarter. Lagoda Investment Management L.P. boosted its stake in shares of VolitionRX by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after purchasing an additional 782,000 shares in the last quarter. Finally, Armistice Capital LLC increased its holdings in VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.